Barings Hong Kong China Fund
PUBLIC EQUITIES
ISIN
IE00B7JY7551
Minimum Investment
EUR 3,500.00
Fund Size
USD 974.70 Million
As of 31/03/2024
Objective
The Barings Hong Kong China Fund (The “Fund”) is an actively managed Emerging Markets (“EM”) equity strategy. The investment objective of the Fund is to seek long-term capital growth primarily through investment in a diversified portfolio of shares of companies where the predominant part of their income is derived from Hong Kong or China.
Strategy
The Fund will seek to achieve its objective by identifying investment opportunities through a differentiated and innovative investment process using fundamental, bottom-up analysis.
Who Should Invest
The Fund is designed for investors seeking a strategy that targets long-term capital growth by investing primarily in Hong Kong China equities.
Risks
The value of investments can fall as well as rise and investors may not get back the amount originally invested. Investing in Chinese securities is subject to emerging market risks, and may also involve certain custodial risks. Changes in exchange rates between the currency of the Fund and the currencies in which the assets of the Fund are valued may also affect the value of the Fund. The Fund may also use derivatives for investment purposes. These are complex instruments that carry the risk of causing increased volatility in the value of the Fund.
Fund Facts
Fund Type
UCITS Funds
Inception Date
03/12/1982
Domicile
Ireland
Share Class Information
Dealing Frequency
Daily
Management Charges
1.25%
The information available on this website is not an offer to sell or an invitation to apply for this product and is by way of information only, nor is the information available on this website intended as an offering of this product to US Persons. Depending on your jurisdiction, you may not have access to this product. Individual investors should contact their financial advisor before investing in this product. The Key Investor Information Document (KIID), if applicable, must be received and read before investing. All other relevant documents relating to the product such as the Report and Accounts and Prospectus should also be read. The information available on this website does not constitute investment, tax, legal or other advice or recommendation.
